Exact Sciences Shares Fall 5.03% with $260M Volume Ranking 375th as Institutional Moves Diverge

On August 8, 2025, Exact Sciences (NASDAQ:EXAS) closed with a 5.03% decline, marking a 65.03% drop in trading volume to $260 million, ranking 375th in the market. The stock's performance coincided with mixed institutional activity and earnings updates that highlighted both growth and valuation concerns.

Second-quarter results showed revenue rising 16% year-on-year to $811.1 million, with the net loss narrowing significantly to $1.19 million, or $0.006 per share. While revenue exceeded analyst forecasts by 4.7%, the stock faced downward pressure from broader market dynamics and shifting institutional sentiment. Cathie Wood’s ARK ETFs added 1.61 million shares of EXAS in a single day, signaling bullish confidence in the diagnostics sector. However, this was offset by a broader trend of institutional selling, including large-scale exits by Aviva PLC and Pearl River Capital LLC.

Analyst ratings remained polarized, with a “Moderate Buy” consensus but recent downgrades from Benchmark and Jefferies citing valuation concerns. Institutional holdings fluctuated sharply, with some firms increasing exposure while others reduced stakes. The stock’s recent 8.1% weekly decline underscored lingering skepticism about its long-term growth potential despite improved profitability.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day delivered a 166.71% return from 2022 to the present, outperforming the benchmark return of 29.18% by 137.53%. This underscores the role of liquidity concentration in short-term stock performance, particularly in volatile markets.